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Enhanced cardiovascular pressor reactivity to norepinephrine
in mild renal parenchymal disease
CARLO BERETTA-PICCOLI, PETER WEIDMANN, HELMUT SCHIFFL, CHRISTOPH COTTIER,
and FRANç0Is C. REIJBI
Medizinische Universitätspoliklinik, Berne, Switzerland
Enhanced cardiovascular pressor reactivity to norepinephrine in mild
renal parenchymal disease. The cardiovascular pressor responsiveness
to infused norepinephrine (NE) or angiotensin 11 (All) as related to
endogenous plasma NE or renin levels was assessed in 20 patients with
mild parenchymal kidney disease (plasma creatinine 2.20 0.58 mg/dl,
SEM) and in 20 normal subjects approximately matched for sex and
age. The two groups did not differ significantly in mean body weight,
heart rate, blood volume, plasma electrolytes, exchangeable or urinary
sodium, plasma aldosterone, epinephrine and renin levels, or All
threshold or pressor doses. Basal (including pre-infusion) plasma NE
levels, the relationship between plasma NE measured during NE
infusion and the corresponding NE infusion rate, well as the total
plasma clearance of NE (5.0 0.8 vs. 5.5 0.5 liter/mm) also did not
differ significantly betVeen the two groups. In contrast, the threshold or
pressor doses of infused NE decreased significantly in the patients with
kidney disease (94 II vs. 134 14 ng/kg/min and 21 3 vs. 40 7 ng/
kg/mm; P < 0.05). Moreover, based on analysis of covariance, the
individual pressor doses as related to basal plasma NE levels were
distributed differently (P < 0.01) between the patients and normal
subjects. These findings suggest that the kinetics of plasma NE are
unaltered largely in early stage kidney disease. However, such patients
tend to develop an exaggerated pressor responsiveness to NE in the
presence of normal plasma NE levels. This disturbance may favor the
development of hypertension.
Stimulation de Ia réactivité pressive cardiovasculaire a Ia noradrénaline
dans les néphropathies modérées. La rCponse pressive cardiovasculaire
après perfusion de noradrCnaline (NE) ou d'angiotensine II (All) en
fonction des concentrations endogenes de NE ou de rCnine plasma-
tiques a été étudiée chez 20 malades ayant une maladie rénale parenchy-
mateuse modérée (créatininémie 2,20 0.58 (± SEM) mg/dl) et chez 20
sujets normaux d'age et de sexe voisins. Les deux groupes ne differ-
aient pas significativement par Ic poids corporel moyen. Ic rythme
cardiaque, Ic volume sanguin, les electrolytes plasmatiques, le sodium
echangeable ou urinaire, l'aldostérone plasmatique, les niveaux da-
drénaline et de rénine, ou les doses seuils ou pressives d'AII. Les
concentrations plasmatiques de NE basales (y compris les valeurs avant
perfusion), Ia relation entre Ia NE plasmatique mesurCe pendant Ia
perfusion de NE et La vitesse de perfusion de NE correspondante, ainsi
que Ia clearance plasmatique totale de NE (5,0 0,8 contre 5.5 0,5 1/
mn) ne différaient egalement pas entre les deux groupes. A l'inverse, les
doses seuils ou pressives de NE perfusees etaient significativement
diminuées chez les nsalades ayant une néphropathie (94 11 contre 134
14 ng/kg/mn et 21 3 contre 40 7 ng/kg/mn; P 0,05). En outre,
par analyse de covariance, les doses pressives individuelles en fonction
des concentrations plasmatiques basales de NE etaient distribuées
différemment (P < 0,01) entre les malades et les sujets normaux. Ces
résultats suggerent que Ia cinetique de Ia NE plasmatique est en grande
partie inchangée au cours des néphropathies au stade initial. Cependant
les malades tendent a developper une réponse pressive exagérée a Ia
NE en presence de concentrations plasmatiques de NE normales. Cette
anomalie pourrait favoriser le développement d'une hypertension.
Renal lesions may affect blood pressure regulation by several
mechanisms, including disturbances of body sodium-fluid vol-
ume homeostasis and the release of pressor or depressor
substances. Mild increases in extracellular fluid volume or
exchangeable sodium [1, 2] or a positive relationship between
plasma volume and blood pressure [31 have been described in
certain patients with early stage kidney disease and hyperten-
sion; plasma renin activity was found to be normal or increased
[2, 4—91. Subtle abnormalities in the relationship between body
sodium and circulating renin may play a contributory role in the
pathogenesis of this type of hypertension [2]. Moreover, the
duration of pre-existent hypertension could be an additional
determinant of the actual blood pressure level, possibly as a
correlate of adaptive structural alterations in the blood vessel
walls [2, 101. Decreased urinary kallikrein excretion could
reflect the lack of a natriuretic and vasodepressor factor [11].
High blood levels of catecholamines have been described in
some patients with terminal renal failure [12], but the role of
adrenergic pathways in hypertension accompanying early stage
kidney disease is presently unclear.
Evaluation of vasoactive factors should be performed taking
the sensitivity of the target organ into consideration. Under
physiological conditions, pressor effects of angiotensin II or
norepinephrine are related inversely to their blood levels [13—
15]. This may represent an important adaptive mechanism in
normal blood pressure homeostasis. In fact, an increased
pressor responsiveness to norepinephrine in relation to circulat-
ing norepinephrine may play a pathogenic role in borderline or
established essential hypertension [15, 16] or diabetes mellitus
[17]. To gain information on these regulatory systems in early
stage kidney disease, we evaluated plasma catecholamine and
renin levels, cardiovascular pressor responses to norepineph-
rine or angiotensin II, as well as exchangeable body sodium and
blood volume in 20 patients with early stage kidney disease and
normal or high blood pressure.
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Table 1. Clinical and biochemical features of normal subjects and patients with renal diseases (mean + sEM)
Methods
Twenty normal subjects and 20 patients with chronic renal
disease were studied. The normal subjects included six females
and 14 males, ranging in age from 22 to 60 years (mean, 42 3
years, sEM). All were normal volunteers with a blood
pressure consistently below 140/90 mm Hg. The patients includ-
ed seven females and 13 males, ranging in age from 22 to 67
years (mean, 41 3 years). The diagnosis of renal disease,
based on clinical signs, laboratory tests, and, in 11 patients,
renal biopsy findings, was chronic glomerulonephritis in II
patients; chronic pyelonephritis, interstitial nephritis of various
etiology, and nephroangiosclerosis in two patients each; bilater-
al hydronephrosis, reflux nephropathy in one patient each; and
unclear in the last patient who had experienced an episode of
acute oliguric renal failure (acute tubular necrosis) 3 years
previously and since had mildly increased plasma creatinine
levels. All patients were clinically stable and without signs of
congestive heart failure or edema.
To avoid very low or high sodium intakes, all subjects were
instructed to adhere to their usual diet but not to add salt to
their food during the study period [181. Antihypertensive drugs
were discontinued 2 to 4 weeks before study. The following
procedures were performed. Twenty-four-hour urinary sodium
and potassium excretion rates, plasma sodium, potassium and
creatinine, blood volume and exchangeable sodium were deter-
mined, and plasma renin activity, aldosterone, norepinephrine
(NE) and epinephrine levels, blood pressure and heart rate were
measured after 1 hr of recumbency and again after 1 hr of
ambulation, according to our standard procedure [191. One to
five days later, the cardiovascular pressor reactivity to pressor
doses of NE or angiotensin II (All) was determined, as de-
scribed previously from this laboratory [20, 211.
Basal (pre-infusion) levels of blood pressure, heart rate,
plasma NE, and renin activity were determined after a 60-mm
equilibration period with slow intravenous infusion of 5%
dextrose solution in the supine position. The blood samples
were collected between 9 and 11 A.M. An infusion of 1-NE or
All (Hypertensin, Ciba, Basel, Switzerland) was then started
and dosages were titrated to reach two target levels of mean
(NE infusion) or diastolic (All infusion) blood pressure, namely
10 to 15 mm Hg (step 1) and 20 to 30mm Hg (step 2) above basal
blood pressure.
Blood pressure was measured using standard cuff and sphyg-
manometer; each recorded pressure was the mean of three
measurements. Mean blood pressure was calculated as the sum
of the diastolic (phase V) and one third of the pulse pressure.
For determination of cardiovascular pressor reactivity, blood
pressure was registered with the automatic recorder Physio-
metrics SR 2. Plasma and urinary sodium and potassium
concentrations were determined by flame photometer, creati-
nine by autoanalyzer. Blood volume and exchangeable sodium
All
20
Patients with renal diseases
BP < 140/90 mm Hg
7
BP> 140/90 mm Hg
13
Normal
subjects
N 20
Blood pressure, mm Hg
Supine 118/78 2/3
Upright 112/79 3/2
Heart rate, beat5/min
Supine 61 2
Upright 86 3
Body weight, kg 74.5 2.3
Hematocrit, % 43 0.7
Exchangeable sodium. 102 2
Blood volume. % 104 3
Plasma sodium, mmole/Iiter 138.2 0.5
Potassium, mmole/titer 4.2 0.1
Renin activity, ng/,nt/hr
Supine 1.6 0.4
Upright 3.0 0.5
Aldosterone, ng/dI
Supine 5.8 0.9
Upright 28.9 7.0
Norepinephrine, ng/dI
Supine 24.4 2.1
Upright 60.8 4.4
Epinephrine, ng/dl
Supine 3.5 0.4
Upright 7.6 1.0
Creatinine I .04 0.03
Urinary sodium. mmole/24 hr 143 12
Potassium, mmole/24 hr 71 5
Percentage is of mean value of our entire study population [221.
P < 0.05.
P < 0.02.
P < 0.005 versus normal subjects.
144/95
129/93
5/3
5/3
121/83 --
107/79
4/2
6/2
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141/100
4/3
3/4
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4
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1.6
2
4
0.5
t).l
69
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101
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4.2
4.1
1.5
1
3
0.9
0.2
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4.3
÷3
4
5
0.5
0.1
1.8
3.2
0.3
0.4
2.4
4.7
0.5
0.9
1.4
2.4
0.2
0.4
10.7
24.4
2.6d
4.3
18.2
35.5 +
6.5
9.4
7.10
18.6
1.7
8.8
32.1
61.2
3.9
8.3
22.8
51.0
3.8
10.2
37.3
65.5
5.5
11.8
2.9
4.7
2.22
164
53
0.3
0.4C
0.58c
19
4d
2.7
4.4
1.29 +
143
57
0.5
0.5'
0.14
37
5"
2.9
4.9
2.65
171
51
0.4
0.5
0.86
2P'6
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were measured by standard isotope dilution technique using
'251-human serum albumin and 24Na, respectively, and ex-
pressed in relation to body surface area using normal ranges
previously established in 99 normal subjects [22]. Plasma renin
activity and aldosterone were measured by radioimmunoassay
[23, 241, NE, and epinephrine by a radioenzymatic method [18,
251. The plasma clearance of NE was calculated as reported
previously from this laboratory [261. Threshold (the extrapolat-
ed dose causing zero change in mean or diastolic blood pres-
sure) and pressor (the dose necessary to elevate mean or
diatolic blood pressure by 20 mm Hg) doses of infused NE or
All were calculated from the dose response curves relating
mean or, respectively, diastolic blood pressure to NE or All
dose rates. Glomerular filtration rate (GFR) and effective renal
plasma flow were measured by constant infusion clearance
method using 51Cr-ethylenediamine tetra-acetate and para-ami-
no hippuric acid, respectively [27]; the interval between the
renal clearance studies and the special studies specified above
was 2 to 4 weeks. For t test, z test (two-tailed), or regression
analysis, the natural logarithm transformation of plasma renin
activity, aldosterone, catecholamines, or threshold and pressor
doses was used. Correlations were compared by analysis of
covariance.
Results
Basal clinical and biochemical findings. Under basal condi-
tions, normal subjects and renal patients did not differ signifi-
cantly in mean heart rate, body weight, hematocrit, blood
volume, exchangeable sodium, plasma sodium, potassium, re-
nm and NE levels or urinary sodium excretion rates (Table 1).
Supine-taken plasma aldosterone tended to be higher, and
upright-taken plasma epinephrine levels or urinary potassium
was slightly lower in the patients. The measured parameters did
not differ significantly between renal patients with normal or
high blood pressure (Table I). However, hypertensive patients
tended to have higher supine-taken plasma NE levels and 24-hr
urinary sodium excretion rates than normal subjects.
Plasma creatinine averaged 2.2 mg/dl (range, 0.80 to 4.5 mg/
dl) in the patients with renal disease and increased (>1.3 mg/dl)
in eight of them. There was a somewhat greater increase in the
subgroup with hypertension while mean plasma creatinine in
the normotensive subgroup was only slightly higher than in
normal subjects (difference not significant; Table 1). GFR and
the effective renal plasma flow were measured in 16 patients
and averaged 71 9 (± SEM) ml/min/1.73 m2 (range, 13 to 157
ml/min/l.73 m2) and 322 56 ml/min/l.73 m2 (range, 27 to 909
ml/min/l.73 m2), respectively; normal ranges in our laboratory
are 126 17 and 646 84 ml/min/l.73 m2 [27]. GFR was lower
than the normal range in 14 of the 16 patients, the effective renal
plasma flow in 15 of them. Both GFR and effective renal plasma
flow tended to be lower in the patients with high blood pressure
(60 10 and 270 44 ml/min/l .73 m) than in those with normal
blood pressure (89 15 and 407 105 ml/min/l.73 m2). Of the
four patients in whom constant infusion clearance measure-
ments could not be performed, only one had a normal plasma
creatinine (0.8 mg/dl) while increased values were noted in the
other three (1.35, 1.75 and 4.5 mg/dl, respectively). Thus, 18 of
the 20 patients had at least some degree of impairment in GFR
and/or effective renal plasma flow.
Norepinephrine infusion study. The basal (pre-infusion) plas-
Table 2. Norepinephrine infusion in normal subjects and patients with renal diseases (mean sEM)
Patients with renal diseases
Normal -
subjects All BP < /40/90 mm Hg BP> 140/90 mm Hg
Norepinephrine dose rate, ng/kg/min
Step 1 88 10 53 6c 55 6c 49 7d
Step 2 198 18 138 + 14" 129 13h 146 20
Plasma norepinephrine, ng/dl
Basal 23.5 1.9 25.4 3.2 18.9 4.5 28.9 4.2
Step 1 183 34 116 16 115 12 116 26
Step 2 402 6 281 37 260 35" 294 56
Mean blood pressure, mm Hg
Basal 88 2 104 4" 92 2 110 ÷ 5'
Step 1 102 2 117 4 105 5 122 5
Step 2 116 9 132 5 121 5 138 5
Heart rate, beats/mm
Basal 61 3 66 2 67 5 64 2
Step 1 55 * 2 58 8 59 3 57 3
Step 2 52 2 54 2 53 3 55 2
Norepinephrine threshold dose,
ng/kglmin 40 7 21 3" 16 2" 23 5b
Norepinephrine pressor dose,
ng/kg/min 134 ÷ 14 94 Il" 76 13' 104 15
Norepinephrine plasma clearance,"
liter/mm 5.5 0.5 4.8 0.6 4.3 0.7 5.0 0.8
Terms: Basal, pre-infusion: step I, norepinephrine infusion rate increasing mean blood pressure by 10 to 15
infusion rate increasing mean blood pressure by 20 to 30 mm Hg.
a Numbers represent average of steps I and 2.
P < 0.05.
P < 0.01.
P < 0.005 versus corresponding value in normal subjects.
mm Hg; step 2, norepinephrine
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Fig. 2. Correlation between norepinephrine pressor dose and pre-
infusion plasma norepinephrine levels in normal subjects and patients
with kidney disease. The straight line represents the regression line
calculated for the 20 normal subjects included in the present study. The
dotted line represents the regression line calculated for 60 normal
subjects studied previously [16, 171 in our laboratory (r = 0.47; P <
0.005).
threshold (25 5 vs. 16 3 ng/kg/min), or pressor dose (103
15 vs. 82 17 ng/kg/min).
To account for the modulating effect of andogenous plasma
NE levels on cardiovascular responsiveness to NE [15], indi-
vidual pressor doses were analyzed in relation to corresponding
basal (pre-infusion) plasma NE concentrations. The NE pressor
dose correlated positively with the basal plasma NE levels in
normal subjects (r = 0.60; P < 0.01), but a positive relationship
in the patients did not reach statistical significance (r = 0.32; P
> 0.05). Based on analysis of covariance, the distribution of
individual values of NE pressor dose as related to basal plasma
NE levels was found to differ significantly (F = 8.35; P < 0.01)
between normal subjects and renal patients (Fig. 2). Values
from 19 of the 20 patients were distributed below the regression
line obtained in the present normal control group or a larger
group of 60 normal subjects studied previously in our laboratory
16, 17] (Fig. 2).
In renal patients, basal plasma NE concentrations tended to
increase while plasma NE clearance tended to decrease with
aging (r = 0.46; P < 0.05 and r = —0.63; P <0.001 respective-
ly). A similar trend in normal subjects did not reach statistical
significance (r = 0.30 and —0.29). No significant correlation
between age and basal plasma NE or NE pressor dose, or
between GFR, effective renal plasma flow or urinary sodium
excretion and basal plasma NE, plasma NE clearance or NE
pressor dose were noted in the two study groups.
Angiotensin II infusion study. The basal (pre-infusion) plas-
ma renin activity did not differ between normal subjects and
renal patients (Table 3). The All infusion dose rates required to
elevate the diastolic blood pressure to the two target levels
I I I
10 20 50 100 200 500
Norepinephrine dose, ng/kg/min
Fig. 1. Correlation between plasma norepinephrine and norepinephrine
infusion rates in normal subjects and patients with kidney disease. The
straight line is the regression line for normal subjects, the dotted line
that for renal patients.
ma NE levels were similar in the normal subjects and patients
with renal disease (Table 2). The NE infusion dose rates
required to elevate the mean blood pressure to the two target
levels (+10 to +15 mm Hg at infusion step 1 and +20 to +30
mm Hg at infusion step 2) were lower in renal patients than in
normal subjects; a similar tendency was noted for plasma NE
concentrations. However, the NE-induced increases in mean
blood pressure and decreases in heart rate were similar in the
two study groups at both infusion steps 1 and 2 (Table 2).
In normal subjects and renal patients, there was a highly
significant correlation between NE infusion dose rates and the
concomitant plasma NE levels. This relationship did not differ
significantly between the two groups (Fig. 1). When the total
plasma clearance of NE was calculated from the infusion rates
and the associated changes in plasma NE concentration, this
parameter did not differ significantly between the lower (step 1)
or higher (step 2) infusion rates in normal subjects (5.5 0.6 vs.
5.6 0.1 liter/mm, respectively) and in the patients (5.3 0.7
and 4.4 0.5 liter/mm). Plasma NE clearance calculated as the
average of the two infusion rates did not differ significantly
between normal subjects and renal patients (Table 2).
Threshold and pressor doses of infused NE were calculated
from dose-response curves relating mean blood pressure to NE
dose rates. Both NE threshold and pressor doses were lower in
the patients than in normal controls (Table 2), while the
steepness (slope) of the dose-response curve was on average
comparable between the two groups (15 1 vs. 17 2).
Basal (pre-infusion) NE levels, plasma NE clearance, NE
threshold and pressor doses did not differ significantly between
the seven patients with normal blood pressure and the 13 with
high blood pressure but tended to be lower in the former (Table
2). Furthermore, the 11 patients with chronic glomerulonephri-
tis and the nine patients with other renal diseases did not differ
in mean basal plasma NE levels (23.5 4.8 vs. 27.6 4.6 ng/
dl), NE plasma clearance (4.2 0.6 vs. 5.3 1.1 liter/mm), NE
Angiotensin II dose rate, nglkg/min
Step 1 4.4 0.6 3.2 0.5 3.7 0.5 2.9 0.4
Step 2 13.5 1.4 9.3 1.3a 11.9 3.0 7.8 l.lb
Plasma renin activity, nglrnl/hr
Basal 1.7 0.3 2.0 0.3 2.6 0.5 1.7 0.4
Step 1 1.0 0.2 1.9 0.3 2.4 0.5 1.5 0.4
Step 2 1.0 0.2 1.6 0.2 1.8 0.3 1.5 0.4
Diastolic blood pressure, mm Hg
Basal 72 2 86 3" 75 3 93 4'
Step 1 84 2 99 3 89 4 104 4
Step 2 94 2 109 3 99 3 114 4
Angiotensin 11 threshold dose,
ng/kglmin 1.4 0.2 1.1 0.2 1.2 0.5 1.0 0.1
Angiotensin II pressor dose,
ng/kglmin 11.1 1.4 8.3 1.2
-
8.1 1.3 8.3 1.8
Terms: Basal, pre-infusion; step 1, angiotensin II infusion rate increasing diastolic blood pressure by 10 to 15 mm Hg; step 2, angiotensin 11
infusion rate increasing diastolic blood pressure by 20 to 30 mm Hg.
P < 0.05.
b P < 0.01 versus corresponding value in normal subjects.
(namely + 10 to + 15 mm Hg at infusion step 1 and +20 to +30
mm Hg at infusion step 2) tended to be lower in the renal
patients than in normal controls (Table 3). Mean basal heart rate
was 66 3 beats/mm in normal subjects and 69 2 beats/mm in
the patients and did not change significantly during All infu-
sion. The higher dose rates of All infusion induced a mild but
significant decrease in plasma renin activity (P <0.005) in both
groups.
Threshold and pressor doses of infused All tended to be
slightly though not significantly lower in the patients than in
normal subjects (Table 3); the steepness of the dose-response
curve relating diastolic blood pressure to All dose rates was on
average comparable (12 2 vs. 11 1).
Basal plasma renin activity and All threshold or pressor
doses did not differ between patients with normal or high blood
pressure (Table 3). Furthermore, the 11 patients with chronic
glomerulonephritis did not differ from the patients with other
renal diseases in basal plasma renin activity (2.3 0.4 vs. 1.4
0.3 nglml/hr) and All threshold (1.6 0.6 vs. 1.5 1.2 ng/kgl
mm) or pressor (8.4 1.2 vs. 8.0 2.5 ng/kg/min) dose.
Discussion
Compared with 20 normal subjects approximately matched
for sex and age, our 20 patients with chronic renal diseases and
mild renal functional impairment (GFR 71 9 ml/min/l.73 m2
and effective renal plasma flow 322 56 mI/mm/I .73 m2) had a
similar mean total blood volume, exchangeable sodium, plasma
renin activity, pressor responsiveness to All, and blood levels
of endogenous NE but responded to a distinctly lower dose of
exogenous NE. The latter conclusion was supported by the
findings of (1) a significant decrease in the NE infusion rates
required to induce identical pressor responses in renal patients
as compared to normal subjects, (2) a significant decrease in the
mean NE threshold and pressor doses in the former, and (3) a
significantly different distribution of individual NE pressor
doses in relation to endogenous plasma NE levels between the
two study groups. Nevertheless, a considerable overlap be-
tween the values from normal subjects and patients points to
heterogeneity within the renal disease group. Thus, seven of
our patients had NE pressor doses related to basal plasma NE
levels below the range observed in normal subjects, while the
others had pressor doses within the low-normal range. A similar
overlap with the normal state also was noted in other diseases
with exaggerated cardiovascular NE reactivity, such as essen-
tial hypertension [15, 161 or diabetes mellitus [171. The present
findings suggest that early stage kidney disease may represent
yet another clinical situation accompanied by NE hyper-re-
sponsiveness, at least in some patients.
The cardiovascular hyper-responsiveness to NE in our pa-
tients with kidney disease was unrelated to the age, the degree
of renal functional impairment, or the etiology of the renal
disease. The increased reactivity to NE also could not be
explained by altered kinetics of plasma NE, disturbed cardiac
innervation, or altered baroreceptor sensitivity [28, 291. Thus,
the relationship between the rates of intravenously infused NE
and corresponding NE plasma concentrations, the total plasma
clearance of NE, as well as the heart rate under basal conditions
and during NE infusion, were all similar in our normal subjects
and renal patients. An association between exaggerated pressor
responsiveness to NE and sodium retention was observed in
certain diseased states such as diabetes mellitus or primary
hyperaldosteronism [17, 30]. Despite the lack of a statistically
significant difference, there was a tendency toward slightly
higher values of exchangeable body sodium in our renal patients
as compared with normal subjects. Although a small part of the
sodium pool is nonexchangeable or slowly exchangeable [31,
321, estimation of body sodium by isotope dilution technique
provides a sensitive method and detects subtle abnormalities.
Thus, exchangeable sodium is modified by changes in dietary
sodium intake [33, 341, is increased in the presence of mild to
severe renal functional impairment [2, 35], and may be de-
creased by pressure-mediated natriuresis in unilateral renal
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Table 3. Angiotensin II infusion in normal subjects and patients with renal diseases (mean 5EM)
Patients with renal diseases
Normal subjects All BP < 140/90 mm Hg BP> 140/90 mm Hg
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artery stenosis [36]. On the other hand, urinary sodium excre-
tion, usually considered an index of dietary intake, was only
slightly and not significantly higher in our patients as compared
with normal subjects. Variations within this range are not
associated with relevant changes in overall sympathetic activi-
ty, as judged by urinary excretion rates and plasma levels of
norepinephrine [18, 37, 38]. The lack of correlation between
urinary sodium excretion and pressor responsiveness to NE
also provided no support for a role of modest variations in
sodium intake in the altered cardiovascular reactivity in our
patients.
Other potential mechanisms of increased responsiveness to
NE include a disturbance of cation metabolism in cardiovascu-
lar smooth muscle cells, a deficiency of vasodilator prostaglan-
din I or kinins, vascular structural alterations secondary to pre-
existing hypertension or retention of uremic toxins. It has been
suggested, although unproven, that some or all of these factors
may play a role in the pathogenesis of essential hypertension
110, 39—411, which also is associated with increased NE pressor
responsiveness in the presence of usually normal plasma NE
concentrations [15, 16]. In patients with early stage kidney
disease, no data are available on intracellular contents of
sodium and calcium or on levels of prostaglandin I or kinins in
blood or vascular tissue. Nevertheless, urinary excretion of
kallikrein was reported to be decreased in hypertensive patients
with mild renal failure [11]. In contrast, urinary prostaglandin E
levels were found to be increased in moderate renal functional
impairment [42], but the meanings of this finding are still
unclear. A major role of adaptive vascular changes secondary
to pre-existing hypertension is unlikely from the present find-
ings. Thus, a tendency for increased NE responsiveness as
related to plasma NE also was noted in the subgroup of renal
patients with normal blood pressure; six out of seven patients
had values below the regression line obtained from the normal
control group. Pressor hyper-responsiveness in early stage
kidney disease may not be limited to NE but has also been
noted in response to calcium infusion in both normotensive and
hypertensive patients [43, 44]. A causal relationship between
these findings should be considered since calcium plays a key
role in the mechanism of NE-induced smooth muscle cell
contraction [45]. Finally, the absence of significant correlation
between cardiovascular responsiveness to NE and the degree of
renal functional impairment does not support the possibility of a
pathogenic role for uremic toxins. Whatever the exact underly-
ing mechanism, the present observation suggests that an exag-
gerated NE pressor responsiveness may contribute and perhaps
even precede the development of hypertension in some patients
with early stage kidney disease.
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